Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on May 9, 2018. The registrant is a Delaware corporation headquartered in Los Angeles, California, and is classified as an Emerging Growth Company. The report details strategic actions regarding the company's intellectual property portfolio.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate event (Item 8.01) and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the expansion of the company's intellectual property strategy:
- Patent Filings: On May 9, 2018, BioSig filed one "omnibus" hardware and software patent application with multiple claim sets and a graphical user interface (GUI) design patent.
- Strategic Partners: The company retained Sherpa Technology Group (IP strategy) and Sterne Kessler Goldstein & Fox P.L.L.C. (patent law) to execute this strategy.
- Scope: The filings cover apparatus, methods, and systems in EP and general signal processing areas, alongside display patents for GUI innovations.
Outlook, Risks, and Management Commentary
Future Plans: Management intends to expand these filings into a robust patent family with multiple domestic and international patents. The company may utilize USPTO acceleration programs (Track One) and the Patent Cooperation Treaty to shorten grant times.
Risks and Contingencies: The report includes standard forward-looking statement disclaimers. Specific risks cited include:
- Inability to manufacture product candidates on a commercial scale.
- Difficulties in obtaining financing on commercially reasonable terms.
- Changes in competition size and nature.
- Loss of key executives or scientists.
- Difficulties in securing regulatory approval for product candidates.
Investor Verification Checklist
- Verify the exact scope and claim sets of the "omnibus" patent application filed on May 9, 2018.
- Confirm the status of financing given the disclosed risk of obtaining funds on reasonable terms.
- Review the company's most recent Form 10-K and 10-Q for detailed financial health and risk factors not covered in this 8-K.
- Monitor progress on regulatory approvals for product candidates, as this is a stated material risk.